Leriglitazone

DB15021InvestigationalSmall molecule

Leriglitazone is under investigation in clinical trial NCT03917225 (A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients).

Chemical structure of Leriglitazone
Mechanism
Curator reviewed
Formula / weight
C19H20N2O4S · 372.438 g/mol (avg)
Also known as
Hydroxypioglitazone
Code names
MIN-102

Resolves to

Compound
UNIIK824X25AYACAS146062-44-4ChEMBLCHEMBL1267ChEBI82937
Clinical / RWD
ATCA16AX23
Structure
InChIKeyOXVFDZYQLGRLCD-UHFFFAOYSA-NSMILESCC(O)C1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
Targets
P37231PPARG

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
4Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Marketed productAcross 1 country and 1 labeller
Sign in
1ATC codeIncluding every combination product, plus 4 drug categories
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Leriglitazone, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In